'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is nearing mainstream adoption for B-cell malignancies due to clinical success.
• Current CAR T-cell efficacy in B-cell cancers depends on the specific CD19 antigen target.
• Commercialization efforts are actively underway for CAR T-cell therapies.

Purpose of the Study:

• To explore alternative targeting strategies for CAR T-cell therapy beyond antibody-based approaches.
• To evaluate the potential of non-antibody CAR designs, such as those utilizing receptors and ligands, for cancer treatment.
• To compare the distinct characteristics and target profiles of different CAR T-cell targeting methods.

Main Methods:

• Investigated CAR T-cell constructs employing receptor-ligand interactions for target recognition.
• Examined the specificity and binding kinetics of non-antibody CAR designs.
• Utilized NKG2D and Erb-B as specific examples of alternative targeting moieties.

Main Results:

• Demonstrated that non-antibody targeting approaches can provide alternative specificities and binding kinetics for CAR T-cells.
• Highlighted the distinct target profiles offered by NKG2D-based and Erb-B-based CAR T-cell therapies.
• Showcased the versatility of CAR T-cell technology beyond CD19-specific targeting.

Conclusions:

• CAR T-cell therapy can be effectively targeted using non-antibody methods, expanding therapeutic options.
• Receptor and ligand-based CARs offer diverse characteristics suitable for various cancer types.
• These alternative strategies hold potential for broadening the application of CAR T-cell therapy in oncology.